PYOTT DAVID E I sold $351K of ALNY
PYOTT DAVID E I sold 1,175 shares of ALNYLAM PHARMACEUTICALS, INC. (ALNY) at $298.91 ($0.35M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure may marginally influence sentiment, but it is not a fundamental catalyst by itself.
Market read
A single director sale under a 10b5-1 plan is generally low-impact; traders may treat it as background noise unless paired with other negative catalysts.
What to watch
The article doesn’t state whether the director’s total holdings changed materially over time or whether other insiders/funds made offsetting moves.
Background
This is an SEC Form 4 insider transaction disclosure (director; open-market sale) including execution details and confirmation of a pre-arranged 10b5-1 plan.
Ticker impact
Alnylam’s director sold 1,175 shares in an open-market transaction under a pre-arranged 10b5-1 plan, disclosed via SEC Form 4.
Likely limited, short-lived impact; any move would be dominated by broader biotech catalysts rather than this Form 4.
The filing provides a specific sale price/date and confirms a pre-arranged 10b5-1 plan, which reduces the likelihood of information-driven trading.
Market effects
Minimal—this is company-specific insider activity with no stated operational/clinical/regulatory change.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can coincide with periods of valuation risk or portfolio rebalancing; monitor for clustering of similar filings.
Key entities
- public_companyALNY
Alnylam Pharmaceuticals, Inc.; issuer of the insider Form 4 transaction.
- insiderPYOTT DAVID E I
Director who sold 1,175 shares on 2026-06-01 under a 10b5-1 plan.
